Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 in chronic hepatitis B
NCT02065336Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Jan 2017
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of ARC-520 in Chronic Hepatitis B (CHB), sponsored by Arrowhead Pharmaceuticals. Started Mar 2014; status: terminated.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02065336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065336.